Navigation Links
Aeolus Pharmaceuticals Announces Successful Completion of Multiple,Dose Safety Study of AEOL 10150

ALS subjects. The continuous delivery of compound by weight adjusted dosing by osmotic infusion pump appears to be an option for subsequent trials and will require the use of an isotonic drug delivery solution.

About Aeolus Pharmaceuticals.

Aeolus is developing a variety of therapeutic agents based on its proprietary small molecule catalytic antioxidants, with AEOL 10150 being the first to enter human clinical evaluation. AEOL 10150 is a patented, small molecule catalytic antioxidant that has shown the ability to scavenge a broad range of reactive oxygen species, or free radicals. As a catalytic antioxidant, AEOL 10150 mimics and thereby amplifies the body's natural enzymatic systems for eliminating these damaging compounds. Because oxygen-derived free radicals are believed to have an important role in the pathogenesis of many diseases, Aeolus' catalytic antioxidants are believed to have a broad range of potential therapeutic uses.

The statements in this press release that are not purely statements of historical fact are forward-looking statements. Such statements include, but are not limited to, those relating to Aeolus' product candidates, as well as its proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aeolus' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Important factors that could cause results to differ include risks associated with uncertainties of progress and timing of clinical trials, scientific research and product development activities, difficulties or delays in development, testing, obtaining regulatory approval, the need to obtain funding for pre-clinical and clinical trials and operations, the scope and validity of intellectual property protection for Aeolus' product candidates, proprietary technologies and their uses, and c
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Study Demonstrating Aeolus Compounds Neuroprotection in Parkinsons Disease Published in the Journal of Neuroscience
2. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
3. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
4. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:7/23/2008)...Pharmaceuticals (SPI) has filed,an Investigational...l,testing of a proprietary formulation of ebselen ... loss or ototoxicity. The oral capsule,containing ...e lung cancer,and head and neck cancer patients re...e second development program for SPI to enter clin...
(Date:7/23/2008)... Have Greater Concentrations of,Stem Cells, ARLIN.../ -- Fat removed,from the lower abdomen and inner ...lent source of stem cells, with higher stem cell c...s a Brazilian-based study in August,s,Plastic and ...urnal of the,American Society of Plastic Surgeons ...
(Date:7/23/2008)...th Protein Therapeutics that Modulate Al..., Mass., July 23 /- Taligen Therapeut...ate growth plan with the,appointment of Abbie Celn...tablishment of its headquarters in Cambridge, Mass...-founder of the company who remains president., U...
(Date:7/22/2008)...nin Medical, a leading innovator,of physiological ...ntered,the clinical testing phase with its breakth...tion. Today,s most common application for this,tec...al blood oxygenation,in the brain -- cerebral oxim...going clinical study at the,Duke University Medica...
Breaking Medicine Technology:Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2Want a Reason to Love Your Lower Belly Fat? It's Rich in Stem Cells 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 1Symmetry Medical Delays 10 K Filing to Complete Review 15357 2Symmetry Medical Delays 10 K Filing to Complete Review 15357 3Symmetry Medical Delays 10 K Filing to Complete Review 15357 4Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 1Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 2Keryx Biopharmaceuticals Announces Termination of SUN MACRO Phase 4 Trial 1608 3Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 1Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 2Wildcat Power Cord repairs cruciate ligament in dairy cows knee 2649 3Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 1Immucor Schedules Third Quarter Earnings Release and Conference Call 15345 2
...Annual Meeting of the American,Psychiatric Associa...all/ -- In adults with,major depressive disorder, ...) resulted in significant improvement in the prima...ing Scale (MADRS),Total Score. In this six-week, r... at the 160th Annual Meeting of the American,Psych...
...ewswire/ -- Asenapine -- an,investigational drug b...siness unit of Akzo Nobel, for bipolar I disorder ...ffective than placebo,in treating acute manic and ... according to new Phase III results, from a study,...s 2007 Annual,Meeting. , In the three-week study, ...
Other Medicine Technology:Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 2Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 3Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 4Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 5Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 6Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 7Six-Week Investigational Study In Adults With Major Depressive,Disorder Evaluates The Effectiveness of Adjunctive Aripiprazole,Therapy With Antidepressants 8Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 2Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 3Organon's Asenapine Effective in a Phase III Study for the,Treatment of Bipolar I Disorder; Results Unveiled at 2007 APA,Meeting 4
(Date:7/25/2008)...Robert J. Reilly, Joins Aethon Team, PITTSBURGH, ...ethon.com ), the leading developer of mobile robot...ounced that Robert J. Reilly has,joined the compan...cer., Reilly, who was most recently Vice Presiden...ecialty Pharmacy Division, brings more than 30,yea...
(Date:7/25/2008)...an cause immune system changes , , FRIDA...linking gastroesophageal reflux disease (GERD) and...ical Center researchers. , An association betwe..., and since then studies have shown that between 5...xperience GERD symptoms. But the actual link betwe...
(Date:7/25/2008)...mation Association (DIA) and the Food and Drug Adm...iative (CPI) on the Move: Complexities and Challen...cal Path Transporter Workshop (October 2-3; North ... PA (PRWEB) July 25, 2005-- The http://www.diahom...he Food and Drug Administration (FDA) will host th...
(Date:7/24/2008)...wswire/ -- Speaker Nancy Pelosi,released the follo...Lantos,and Henry J. Hyde Global Leadership Against...on Act of 2008. The bill, which passed the Senate ... of 303 to 115 and will now go,the President for h...historic vote to pass landmark legislation to,reau...
Breaking Medicine News(10 mins):Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:People With GERD More Likely to Develop Asthma 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 2Health News:DIA And FDA To Host Two Important Critical Path Workshops 3Health News:Pelosi Statement on House Passage of Global AIDS Legislation 2
...g rod of Chikungunya, the ruling Left Democratic... quest for a 'politically correct' low-cost health...Front (LDF) government had dumped its BPL (below p...CI Lombard to seek out a cost-competitive, quality...
... lymphoma became substantially more common in the ... a report in the July issue of Archives of Dermato...nd geographic area. Cutaneous T-cell lymphoma occ...tem (called T lymphocytes) become cancerous and af...
...t his 90 day stint at the Betty Ford clinic in Pal...to Nicole Kidman from collapsing . The singer ent... after the couple wed in June that year. Urban ho...tering rehab at the time was one of the wisest dec...
...ssage in one ear while a friend is talking into yo... an important communication skill thats heavily in...ional Institute on Deafness and Other Communicatio...l Institutes of Health. The finding, published in...
Other Medicine News:Health News:Kerala Government Battles With Chikungunya On All Counts 2Health News:Cutaneous T-cell Lymphoma Shows Steady Increase 2Health News:Genes Influence the Ability to Listen Two Things at a Time 2Health News:Genes Influence the Ability to Listen Two Things at a Time 3
... is recommended for separations of DNA fragments <...at are easy to handle, and remains flexible even a...f cracking or breaking. Certified PCR agarose, unl...ilar sieving properties, is a standard gelling tem...
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum
Agarose-HR™ High Resolution - Efficiently separates DNA fragments from 50 to 1000 bp. It is useful for sizing PCR fragments, small DNA fragments generated by restriction enzyme digestion, and d
...ning donors on the PK7200 Automated Microplate Sys...d to a gelatin particle for the detection of cytom...f the CMV assay as compared to EIA measures 99.8% ...cle as the carrier provides excellent lot-to-lot c...
Medicine Products: